Other Information
−Removed: Insider Trading Arrangements
−Removed: For the quarter ended March 31, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or a “non-Rule 10b5 - 1 trading arrangement” (each as defined in Item 408 (a) and (c), respectively, of Regulation S-K).
+Added: (c) During the quarter ended June 30, 2024, the following individuals adopted Rule 10b5 - 1 trading arrangements, which are intended to satisfy the affirmative defense of Rule 10b5 - 1 (c) under the Exchange Act:
+Added: our President and Chief Executive Officer Mark Emalfarb ( adopted on June 4, 2024 ); our director Jack Kaye ( adopted on June 6, 2024 ); our Vice President of Research and Business Development Ronen Tchelet ( adopted on June 7, 2024 ); and our Chief Financial Officer Ping Wang Rawson ( adopted on June 12, 2024 ).
+Added: Each trading arrangement includes the potential sale of up to a specified number of shares of our common stock owned by the applicable individual (for Mr.
+Added: Emalfarb, 1 million; for Mr.
+Added: Kaye, 292,367; for Mr.
+Added: Tchelet, 250,000; and for Ms.
+Added: Rawson, 282,485 ), and expires on a specified date (for Mr.
+Added: Emalfarb, December 31, 2026; for Mr.
+Added: Kaye, June 2, 2026; for Mr.
+Added: Tchelet, June 10, 2025; and for Ms.
+Added: Rawson, June 12, 2026), unless earlier terminated in accordance with the provisions of the arrangement.
+Added: Except as described above, for the quarter ended June 30, 2024, none of our directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or a “non-Rule 10b5 - 1 trading arrangement” (each as defined in Item 408 (a) and (c), respectively, of Regulation S-K).
The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:
6 unchanged sentences
March 29, 2023
−Removed: Form of Senior Secured Convertible Promissory Note due March 8, 2027
−Removed: March 11, 2024
−Removed: Securities Purchase Agreement (1)
−Removed: March 11 2024
−Removed: Registration Rights Agreement (1)
−Removed: March 11, 2024
−Removed: Security Agreement (1)
−Removed: March 11, 2024
−Removed: Subsidiary Guarantee (1)
−Removed: March 11, 2024
+Added: License and Development Agreement between Dyadic International (USA), Inc.
+Added: and Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals, dated June 27, 2024 (1)
Certification of Principal Executive Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
11 unchanged sentences
(1) Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.
−Removed: The Company hereby undertakes to provide on a supplemental basis an unredacted copy of the exhibit to the SEC upon request.
(2) Furnished herewith.
1 unchanged sentence
DYADIC INTERNATIONAL, INC.
+Added: August 13, 2024
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 13, 2024
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.